KBA-1413

N/A

Report date: 2023/12/22 12:00:23

Base Information

Drug NameKBA-1413

Drug Alias NameAT 1413 bivalent antibody immune therapeuticKBA1413KBA-1413AT1413AT1413 BAIT +[10]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Leukosialin

TargetsLeukosialin

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAimm Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesKling Biotherapeutics BV

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A